Mankind Pharma shares in focus after Q3 net profit rises 8%YoY to Rs 414 crore

Mankind Pharma shares are expected to remain in focus on Wednesday after the pharmaceutical major posted an 8% year-on-year rise in consolidated net profit, which stood at Rs 414 crore in Q3FY26, compared with Rs 385 crore in the same quarter last year. Revenue for the quarter grew 11.5% YoY to Rs 3,567 crore, up from Rs 3,199 crore in the corresponding period last year.

On the operational front, domestic revenues rose 11.1% YoY to Rs 3,046 crore, driven by steady growth in the base business and supported by consolidation of BSV. Export revenues increased 14.1% YoY to Rs 521 crore, aided by strong performance in the international BSV business.

The company reported an adjusted EBITDA margin of 25.9%, while PAT margin stood at 11.6% during the quarter. Diluted EPS came in at Rs 9.9, registering a 6.7% YoY growth (face value Re 1).


While domestic revenue growth remained healthy, secondary sales growth stood at 8.5% compared to IPM growth of 11.8%, largely due to underperformance in acute therapies amid ongoing corrective actions.

In the Consumer Healthcare segment, revenue grew 5.2% YoY in Q3FY26, marking a sharp recovery from a 2.6% decline in Q2FY26 and indicating a return to sequential growth momentum. The company also saw a significant increase in modern trade and e-commerce contribution, with the channel share rising to 13.1% in Q3FY26 from 9.8% in Q3FY25, supported by over 40% growth.

On the exports side, revenue growth of around 14% YoY was primarily driven by strong traction in the BSV international business.

Sensex, Nifty today: Catch all the LIVE stock market action here

Additionally, Mankind Pharma (excluding BSV) launched four new products during 9MFY26, taking the total number of products launched in the US to 48, strengthening its long-term growth pipeline.

Overall, the company’s steady earnings growth, margin stability, and improving consumer healthcare performance are likely to keep the stock in focus in the upcoming trading session.

On the technical front, trendline data indicates that the 14-day RSI stands at 51, suggesting a neutral momentum. An RSI reading below 30 signals oversold conditions, while levels above 70 indicate overbought territory.

From a moving average perspective, Mankind Pharma is trading below five of its eight key simple moving averages, reflecting mixed trends. However, the stock remains above its short-term moving averages, including the 5-day, 10-day, and 15-day SMAs, indicating near-term strength.

On Tuesday, the stock ended 4% higher at Rs 2,155.90 on the BSE.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)